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Background: Nipple aspirate fluid (NAF) contains large amounts of protein thought to reflect the
microenvironment of the breast, and is of interest in breast cancer prevention research. The correlation between
specific NAF proteins to plasma concentrations have not been well studied in healthy women. We collected
matched NAF and plasma from 43 healthy pre and postmenopausal women participating in an early phase clinical
study to compare the levels of putative cancer protein biomarkers. We compared baseline NAF and plasma levels
of epidermal growth factor (EGF), transforming growth factor-beta 1 (TGF-β1), and adiponectin and evaluated
menopausal status and body mass index (BMI) as potential modifying factors.
Findings: NAF and plasma levels of EGF, TGF-β1 and adiponectin were not correlated. EGF and TGF-β1 levels in
NAF of premenopausal women were significantly higher than postmenopausal women (P’s < 0.01). These
differences by menopausal status were not observed in plasma. Both NAF and plasma adiponectin levels were
non-significantly higher in postmenopausal women. NAF biomarker levels were not associated with BMI
whereas plasma EGF, TGF-β1 and adiponectin levels in postmenopausal women were all inversely correlated with
BMI (P’s < 0.05).
Conclusions: Protein biomarkers differ significantly between NAF and plasma and are affected differently by both
BMI and menopausal status. This study demonstrates important differences in biological information gained by
characterizing biomarkers in NAF compared to plasma and suggests each sample source may independently inform
on breast cancer risk.Findings
Introduction
Nipple aspirate fluid (NAF) is a rich source of protein
postulated to more closely reflect the local breast micro-
environment than plasma. Petrakis et al. [1] showed that
simply producing NAF doubled a woman’s risk of breast
cancer, which lead to a handful of studies using NAF
as a source of breast tissue risk biomarkers [2-4]. The
components of NAF are regularly metabolized and re-
absorbed by the epithelial lining of the ductal/alveolar* Correspondence: jam1@email.arizona.edu
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reproduction in any medium, provided the orsystem [5]. It is hypothesized that drug, protein and hor-
mone levels in NAF more closely reflects breast tissue
environment and exposures than plasma [6,7]. In women
with breast cancer, Kuerer et al. found no association be-
tween serum and NAF levels of soluble Her-2/neu al-
though the Her-2/neu levels between the affected and
unaffected breasts were highly correlated [8]. Whether
protein levels in NAF of healthy women are correlated
with plasma is largely unknown.
In an effort to better understand the relatedness be-
tween plasma and NAF composition in healthy wo-
men, we conducted a correlative analysis of candidate
breast cancer risk markers in matched NAF and plasma
samples from healthy pre- and postmenopausal womentd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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http://www.biomarkerres.org/content/1/1/18participating in a Phase I clinical trial. Here we report on
our findings for biomarkers previously related to breast
cancer, epidermal growth factor (EGF) [9], transforming
growth factor-beta 1 (TGF-β1) [10], and adiponectin [11].Study participants
We recruited healthy women age 18–65 to a Phase I
trial to evaluate the safety and feasibility of topical appli-
cation of limonene as massage oil to the breast and to
determine limonene levels in NAF. Details of the trial
have been described elsewhere [12]. Participants were
excluded if they were pregnant or breastfeeding, had
invasive cancers within the past 5 years, participated in
another clinical intervention trial within the past 3
months, had uncontrolled metabolic disorders, serious
acute or chronic diseases, or were unable to produce
NAF. The study was approved by the University of
Arizona Human Subjects Committee and written con-
sent was obtained from all participants.Sample collection
Baseline (pre-intervention) NAF was collected via breast
massage and a Medela breast pump into capillary tubes
and immediately diluted in phosphate buffered saline
(1:10). Baseline blood sample was collected into Vacu-
tainer tubes containing sodium heparin and centrifuged
for plasma separation. Plasma and diluted NAF were
stored at -80°C prior to analysis.Table 1 Participant demographicsPlasma and NAF biomarker analysis
NAF and plasma EGF, TGF-β1, and adiponectin were
measured using ELISA based immunoassays (R&D Sys-
tems, Minneapolis, MN, USA). Plasma samples were di-
luted prior to the analysis according to the manufacturer
instructions for EGF and TGF-β1, and were diluted
1:200 for the adiponectin assay. NAF samples were fur-
ther diluted 1:100 – 400 for EGF, 1:20 – 40 for TGF-β1
and 1:3 – 1:20 for adiponectin. Assays were linear over
the concentration range of 3.9 - 250 pg/mL, 31.2 –
2,000 pg/mL, and 3.9 - 250 ng/mL for EGF, TGF-β1, and
adiponectin, respectively. Each sample was analyzed in
duplicate for each assay (CVs <10% for all assays).Premenopausal
women (N = 16)
Postmenopausal
women (N = 27)
Age 45 (41.4 ± 10.9)a 56.0 (56.2 ± 5.0)a
Body Mass Index (kg/m2) 25.3 (27.3 ± 6.0)a 25.1 (25.7 ± 4.6)a
Race/Ethnicity: n (%)
Caucasian 15 (93.7) 24 (88.9)
Pacific Islander 1 (6.3) 0 (0.0)
Native American 1 (6.3) 1 (3.7)
Black 0 (0.0) 2 (7.4)
amedian (mean ± SD).Statistical analysis
Linear regression was performed to control for body
mass index (BMI) while comparing differences between
pre- and postmenopausal in protein biomarker levels in
NAF as well as in plasma. Spearman correlation coeffi-
cients were derived to determine correlations between
NAF and plasma biomarkers as well as BMI and NAF or
plasma protein biomarkers. A P-value of < 0.05 was con-
sidered statistically significant.Participant characteristics
Matched baseline NAF and plasma samples were avai-
lable from 16 premenopausal and 27 postmenopausal
eligible women for the cross-sectional analysis; demo-
graphics are presented in Table 1.
Plasma and NAF biomarker levels by menopausal status
Participants produced a wide range of NAF volume
(3 – 50 μL) and in some participants there was insuffi-
cient NAF sample volume for all three biomarker mea-
surements, yielding 33, 35 and 28 pairs of plasma and
NAF measurements for EGF, TGF-β1 and adiponectin,
respectively. The total protein concentration in NAF also
varied widely among the study participants (13 – 101
mg/mL). Therefore, all NAF protein biomarker measure-
ments were normalized by the total protein concentra-
tion. Figure 1 illustrates matched NAF and plasma
biomarker levels by menopausal status (mean±SD pre-
sented in Additional file 1: Table S1). We corrected for
BMI in all analyses. Postmenopausal women had sig-
nificantly lower EGF (P = 0.004) and TGF-β1 (P = 0.01)
levels in NAF when compared to premenopausal wo-
men. Plasma EGF levels were non-significantly higher in
premenopausal women compared to postmenopausal
while plasma TGF-β1 levels were not different (P = 0.06
and P = 0.69, respectively). Adiponectin levels were non-
significantly higher in postmenopausal women in NAF
(P = 0.15) as well as plasma (P = 0.07).
Plasma and NAF biomarker correlations and relationship
to BMI
None of the plasma biomarker levels were statistically
significantly correlated to NAF levels (Table 2; Additional
file 1: Figure S1). We also examined the correlation bet-
ween levels of EGF, TGF-β1, and adiponectin and BMI by
menopausal status (Table 3: Additional file 1: Figure S2).
NAF biomarkers were not significantly correlated to BMI
in either pre- or postmenopausal women. Plasma mea-
sures of EGF, TGF-β1 and adiponectin were all signifi-
cantly inversely correlated with BMI in postmenopausal
women (P = 0.003, P < 0.001, and P = 0.05; respectively). In




Premenopausal (n = 9) −0.15 0.70
Postmenopausal (n = 24) 0.14 0.51
TGF-β1
Premenopausal (n = 11) −0.35 0.30
Postmenopausal (n = 24) 0.25 0.25
Adiponectin
Premenopausal (n = 6) −0.09 0.87
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Figure 1 Box plots illustrating differences between pre and postmenopausal women in plasma and NAF levels of Epidermal Growth
Factor (EGF; a and b), Transforming Growth Factor Beta1 (TGF-β1; c and d) and Adiponectin (e and f). aP-values derived from linear
regression models with controlling for BMI. bP-values derived from linear regression models with controlling for Adiponectin. cP-values derived
from linear regression models with controlling for BMI and Adiponectin.
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http://www.biomarkerres.org/content/1/1/18premenopausal women, plasma adiponectin was signifi-
cantly inversely associated with BMI (P = 0.02; n = 16).
Analyses of the two-way interaction between BMI and
menopausal status for plasma EGF and TGF-β1 concen-
trations were statistically significant (P = 0.04 and P = 0.01,
respectively).
Discussion
In a cohort of 43 healthy women, we measured the
secreted protein biomarkers EGF, TGF-β1, and adipo-
nectin in matched NAF and plasma samples. Interes-
tingly, none of the three biomarkers in NAF were
correlated to levels in plasma. Further, in postmeno-
pausal women, levels of all three potential breast cancer
biomarkers in plasma were inversely correlated with
BMI, but there was no relationship between BMI and
these biomarkers in NAF. With our small sample size,
correlation coefficients ≥ 0.45 are necessary to determine
Table 3 Association between biomarker levels and BMI
EGF Spearman correlation P-value
NAF
Premenopausal (n = 9) −0.20 0.61
Postmenopausal (n = 25) 0.06 0.79
Plasma
Premenopausal (n = 16) 0.25 0.35
Postmenopausal (n = 27) −0.55 0.003
TGF-β1
NAF
Premenopausal (n = 11) −0.23 0.50
Postmenopausal (n = 26) −0.09 0.68
Plasma
Premenopausal (n = 16) 0.41 0.11
Postmenopausal (n = 27) −0.60 <0.001
Adiponectin
NAF
Premenopausal (n = 6) −0.31 0.54
Postmenopausal (n = 23) 0.15 0.50
Plasma
Premenopausal (n = 16) −0.59 0.02
Postmenopausal (n = 27) −0.39 0.05
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plasma or between biomarkers and BMI with 80% po-
wer. Our sample size, however, was sufficient to de-
termine a statistically significant relationship between
plasma adiponectin levels and BMI, a well-known asso-
ciation [13]. Therefore, this preliminary evidence sug-
gests that NAF contains biological information distinct
from plasma, despite the small sample size.
We are aware of only one other study reporting adi-
ponectin levels in the NAF; Sauter et al. observed that 3
and 6 months after bariatric surgery, NAF adiponectin
levels significantly increased in premenopausal women,
but were unchanged in postmenopausal women [14].
Given the known inverse association between plasma
adiponectin levels and BMI [15] and epidemiological evi-
dence indicating an inverse relationship between adipo-
nectin levels and breast cancer risk [11], it is interesting
that NAF adiponectin levels in postmenopausal women
appear to be independent of BMI in our work as well as
that of Sauter et al.
To our knowledge, this is the first study to quantify
TGF-β1 in NAF. Here TGF-β1 levels in NAF of pre-
menopausal women were significantly higher than post-
menopausal women, whereas plasma levels were similar
between the two groups. These results likely reflect
differential hormone levels in the breast by menopau-
sal status.NAF EGF levels in healthy, pre and postmenopausal
women were similar to those previously reported [16-18].
Our finding of higher EGF levels in NAF of premeno-
pausal women relative to postmenopausal women is con-
sistent with a positive effect of sex hormones on EGF
exposure in the breast [16]; as well as with other studies
which have shown differences in plasma and NAF bio-
markers by sex steroid hormone concentrations [19,20].
While our data suggests that circulating EGF, TGF-β1
and adiponectin in plasma are regulated differently from
NAF protein levels, the main study limitation is the
small sample size. Further, the premenopausal women
enrolled in this study had, on average, a higher BMI
compared to the postmenopausal women. This differs
from the age expected BMI distribution [21], suggesting
a participation bias. We attempted to adjust for this bias
using adiponectin as a surrogate of metabolic distur-
bance [22]. After adjustment for BMI alone, adiponectin
alone, or BMI and adiponectin, there were still signifi-
cant differences in the NAF levels of the study proteins
between pre and post-menopausal women, which were
not observed in plasma. Reproductive variables such as
time since lactation or last full birth may also affect
NAF components [23], however, were not collected as
part of the clinical study. Timing of sample collection
for phase in the menstrual cycle poses another potential
source of variation that was not controlled in this study.
Chatterton et al., however, has demonstrated that levels
of NAF proteins including EGF, cathepsin D, and
interleukin-6 were consistent throughout the phases of
the menstrual cycle [24]. Therefore, it is likely that
the variation in NAF protein levels in premenopausal
women is a reflection of long-term hormonal (and envi-
ronmental) exposures. Taken together, our findings sug-
gest that the underlying biological factors associated
with both BMI and menopausal status differentially in-
fluence protein expression in plasma as compared NAF.
Future studies with larger sample sizes are warranted to
develop the use of NAF as a minimally invasive strategy
to identify risk factors and novel drug/prevention targets
in the breast.Additional file
Additional file 1: Figure S1. Scatter plots illustrating null associations
between plasma and NAF levels in premenopausal and postmonausal
women of Epidermal Growth Factor (EGF; a and b), Transforming Growth
Factor Beta 1 (TGF-β1; c and d) and Adiponectin (e and f). The
appearance of an association between NAF and Plasma levels of TGF-β1
in postmenopausal women (d) seems to be driven by one woman with
very high levels in both NAF and plasma. Figure S2. Scatter plots
illustrating associations between BMI and plasma levels of Epidermal
Growth Factor (EGF; a), Transforming Growth Factor Beta 1 (TGF-β1: b)
and Adiponectin (c) in premenopausal women; between BMI and NAF
levels of EGF (d) TGF-β1 (e) and Adiponectin (f) in premenopausal
women; between BMI and plasma levels of EGF (g) TGF-β1 (h) and
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http://www.biomarkerres.org/content/1/1/18Adiponectin (i) in postmenopausal women; and between BMI and NAF
levels of EGF (j) TGF-β1 (k) and Adiponectin (l) in postmenopausal
women. Table S1. NAF and plasma biomarker levels.
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